| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ebenezer Oloyede, Ivana Clark, Shubhra Mace, Eromona Whiskey, David Taylo. Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review. Therapeutic advances in psychopharmacology. vol 12. 2022-02-03. PMID:35111297. |
only about 50% of patients with treatment-resistant schizophrenia respond to clozapine, and many more patients continue to experience ongoing and prominent negative symptoms. |
2022-02-03 |
2023-08-13 |
Not clear |
| Siobhan Gee, David Taylo. Alternative Routes of Administration of Clozapine. CNS drugs. 2022-02-03. PMID:35113345. |
clozapine is the only antipsychotic with proven effectiveness in treatment-resistant schizophrenia. |
2022-02-03 |
2023-08-13 |
Not clear |
| J P Lindenmayer, Beverly J Insel, Anzalee Khan, McKenzie Osborne, Abraham Goldring, Mary Sedd. Effects of Clozapine on Neurocognitive Functions in Schizophrenia: A Naturalistic Comparison to Non-clozapine Antipsychotics. Innovations in clinical neuroscience. vol 18. issue 10-12. 2022-01-31. PMID:35096483. |
effects of clozapine on neurocognitive functions in schizophrenia: a naturalistic comparison to non-clozapine antipsychotics. |
2022-01-31 |
2023-08-13 |
Not clear |
| J P Lindenmayer, Beverly J Insel, Anzalee Khan, McKenzie Osborne, Abraham Goldring, Mary Sedd. Effects of Clozapine on Neurocognitive Functions in Schizophrenia: A Naturalistic Comparison to Non-clozapine Antipsychotics. Innovations in clinical neuroscience. vol 18. issue 10-12. 2022-01-31. PMID:35096483. |
this study aimed to compare the neurocognitive effects of clozapine treatment to those of non-clozapine antipsychotics in patients with schizophrenia and to examine the role of anticholinergic burden on cognitive impairments. |
2022-01-31 |
2023-08-13 |
Not clear |
| Mahwish Adnan, Fatima Motiwala, Chintan Trivedi, Tania Sultana, Zeeshan Mansuri, Shailesh Jai. Clozapine for Management of Childhood and Adolescent-Onset Schizophrenia: A Systematic Review and Meta-Analysis. Journal of child and adolescent psychopharmacology. 2022-01-31. PMID:35099269. |
clozapine for management of childhood and adolescent-onset schizophrenia: a systematic review and meta-analysis. |
2022-01-31 |
2023-08-13 |
Not clear |
| Masaru Tsukahara, Ryuhei So, Nobuyuki Nomura, Kohei Kitagawa, Yuya Mizuno, Fuminari Misawa, Masafumi Kodama, Hiroyuki Uchida, Masaru Mimura, Hiroyoshi Takeuch. Association between subjective distress and symptom domains in patients with treatment-resistant schizophrenia receiving clozapine. Schizophrenia research. vol 240. 2022-01-27. PMID:35086033. |
association between subjective distress and symptom domains in patients with treatment-resistant schizophrenia receiving clozapine. |
2022-01-27 |
2023-08-13 |
Not clear |
| Laurent Béchard, Olivier Corbeil, Marc-André Thivierge, Ibrahim Assaad, Camille Boulanger, Marie-Pierre Mailhot, Alexis Turgeon-Fournier, Marc-André Roy, Marie-France Demer. Management of Rhabdomyolysis in a Patient Treated with Clozapine: A Case Report and Clinical Recommendations. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 20. issue 1. 2022-01-26. PMID:35078963. |
clozapine has a unique efficacy in treatment-resistant schizophrenia. |
2022-01-26 |
2023-08-13 |
Not clear |
| Laurent Béchard, Olivier Corbeil, Marc-André Thivierge, Ibrahim Assaad, Camille Boulanger, Marie-Pierre Mailhot, Alexis Turgeon-Fournier, Marc-André Roy, Marie-France Demer. Management of Rhabdomyolysis in a Patient Treated with Clozapine: A Case Report and Clinical Recommendations. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 20. issue 1. 2022-01-26. PMID:35078963. |
a 20-year-old caucasian male diagnosed with resistant schizophrenia developed, after a 5-month total exposition and a significant response to treatment, a marked creatine kinase (ck) elevation and important myalgia in the weeks following an increment from 175 to 200 mg of the daily dose of clozapine. |
2022-01-26 |
2023-08-13 |
Not clear |
| Xiaoping Yuan, Song Wang, Yudong Shi, Yating Yang, Yulong Zhang, Lei Xia, Kai Zhang, Huanzhong Li. Pro-inflammatory cytokine levels are elevated in female patients with schizophrenia treated with clozapine. Psychopharmacology. 2022-01-26. PMID:35080634. |
pro-inflammatory cytokine levels are elevated in female patients with schizophrenia treated with clozapine. |
2022-01-26 |
2023-08-13 |
Not clear |
| Xiaoping Yuan, Song Wang, Yudong Shi, Yating Yang, Yulong Zhang, Lei Xia, Kai Zhang, Huanzhong Li. Pro-inflammatory cytokine levels are elevated in female patients with schizophrenia treated with clozapine. Psychopharmacology. 2022-01-26. PMID:35080634. |
the aims of this study were to detect (1) whether serum cytokine levels were altered in patients with chronic schizophrenia after clozapine treatment compared with age- and sex-matched healthy controls, (2) whether there was a gender difference in serum cytokine levels after clozapine treatment, and (3) whether there was a correlation between serum cytokine levels and clozapine daily dosage in patients with schizophrenia. |
2022-01-26 |
2023-08-13 |
Not clear |
| Mark Vickers, Vinay Ramineni, Eva Malacova, Lars Eriksson, Kirsten McMahon, Vikas Moudgil, James Scott, Dan Siskin. Risk factors for Clozapine-induced myocarditis and cardiomyopathy: A systematic review and meta-analysis. Acta psychiatrica Scandinavica. 2022-01-24. PMID:35067911. |
clozapine is the most effective medication for treatment refractory schizophrenia; however, it is associated with severe cardiac adverse events including myocarditis and cardiomyopathy. |
2022-01-24 |
2023-08-13 |
Not clear |
| Ruth Cano-Corres, Siddarta Acebillo, Francesc Campos Barreda, Diego J Palao, Eugenio Berlanga-Escaler. Impact of a Novel Strategy for Critical Values Communication for the Management of Patients Treated with Clozapine. EJIFCC. vol 32. issue 4. 2022-01-20. PMID:35046764. |
clozapine is an antipsychotic drug used to treat resistant schizophrenia and other disorders. |
2022-01-20 |
2023-08-13 |
Not clear |
| Xavier Boland, Luiz Dratc. First Use of Clozapine Point of Care Testing in Acute Inpatient Psychiatry: Preliminary Report. Journal of psychiatric practice. vol 28. issue 1. 2022-01-06. PMID:34989347. |
clozapine is the antipsychotic of choice in treatment-resistant schizophrenia. |
2022-01-06 |
2023-08-13 |
Not clear |
| James L Laws, Esther Kim, Rebecca Hung, JoAnn Lindenfeld, Richa Gupt. Chest Pain in a Psychiatric Patient Due to Clozapine-Induced Myopericarditis. Case reports in cardiology. vol 2021. 2022-01-03. PMID:34976414. |
drug-induced myocarditis is a rare, but underrecognized complication of clozapine therapy for schizophrenia. |
2022-01-03 |
2023-08-13 |
Not clear |
| Mizuki Hino, Takeshi Kondo, Yasuto Kunii, Junya Matsumoto, Akira Wada, Shin-Ichi Niwa, Mitsutoshi Setou, Hirooki Yab. Tubulin/microtubules as novel clozapine targets. Neuropsychopharmacology reports. 2021-12-29. PMID:34964309. |
clozapine is currently the only effective drug for treatment-resistant schizophrenia; nonetheless, its pharmacological mechanism remains unclear, and its administration is limited because of severe adverse effects. |
2021-12-29 |
2023-08-13 |
Not clear |
| Yasin Bez, Sindhura Kompella, Felicia Gallucci, Adam Awerbuch, Barbara J Coffe. Clinical Use of Clozapine Serum Level and Management of Adverse Effects in an Adolescent with Difficult to Treat Schizophrenia. Journal of child and adolescent psychopharmacology. vol 31. issue 10. 2021-12-27. PMID:34958240. |
clinical use of clozapine serum level and management of adverse effects in an adolescent with difficult to treat schizophrenia. |
2021-12-27 |
2023-08-13 |
Not clear |
| Sandeep Grover, Swapnajeet Sahoo, Aseem Mehr. Safe use of Clozapine in a patient with treatment resistant schizophrenia with co-morbid Dilated cardiomyopathy: A case report. Asian journal of psychiatry. vol 68. 2021-12-25. PMID:34953217. |
safe use of clozapine in a patient with treatment resistant schizophrenia with co-morbid dilated cardiomyopathy: a case report. |
2021-12-25 |
2023-08-13 |
Not clear |
| Samantha Christine Sernoskie, Alexandra R Lobach, Ryuji Kato, Alison Jee, J Kyle Weston, Jack Uetrech. Clozapine induces an acute proinflammatory response that is attenuated by inhibition of inflammasome signaling: implications for idiosyncratic drug-induced agranulocytosis. Toxicological sciences : an official journal of the Society of Toxicology. 2021-12-22. PMID:34935985. |
although clozapine is a highly efficacious schizophrenia treatment, it is under-prescribed due to the risk of idiosyncratic drug-induced agranulocytosis (idiag). |
2021-12-22 |
2023-08-13 |
human |
| Robert Løvsletten Smith, Birgit M Wollmann, Lennart Kyllesø, Thu Thuy Anh Tran, Marit Tveito, Espen Molde. Effect of Valproic Acid on the Metabolic Spectrum of Clozapine in Patients With Schizophrenia. Journal of clinical psychopharmacology. vol 42. issue 1. 2021-12-20. PMID:34928560. |
effect of valproic acid on the metabolic spectrum of clozapine in patients with schizophrenia. |
2021-12-20 |
2023-08-13 |
Not clear |
| Maité A Cintrón Pastrana, Erick Quintana Avile. Treatment of Refractory Schizophrenia With Clozapine in a Patient With Wolff-Parkinson-White Syndrome. Journal of clinical psychopharmacology. vol 42. issue 1. 2021-12-20. PMID:34928564. |
treatment of refractory schizophrenia with clozapine in a patient with wolff-parkinson-white syndrome. |
2021-12-20 |
2023-08-13 |
Not clear |